SCHEMBL13288712

SCHEMBL13288712

Bc1cnn2c(NCc3ccc(CNC(=O)c4cccc(Oc5ccccc5)c4)cc3)cc(-c3ccccc3Cl)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 5/20 0.50
▸ GSK3B P49841 4/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ MAPK14 Q16539 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ LOX P28300 2/20 0.39
▸ LOXL2 Q9Y4K0 2/20 0.39
▸ RAF1 P04049 1/20 0.39
▸ PDE2A O00408 1/20 0.39
▸ PDE10A Q9Y233 1/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ RAB9A P51151 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13119514 0.91 CDK2 (0.63) CDK2GSK3B
SCHEMBL12953801 0.91 CDK2 (0.50) CDK2GSK3BSMN1; SMN2LMNAHTT
SCHEMBL13288759 0.90 CDK2 (0.46) CDK2GSK3BSMN1; SMN2LMNALOXL2
SCHEMBL13288882 0.88 CDK2 (0.54) CDK2GSK3BPDE2APDE10A
SCHEMBL13288715 0.88 ALDH1A1 (0.51) CDK2GSK3BHTTMAPK14KMT2A
SCHEMBL13119412 0.87 CDK2 (0.60) CDK2GSK3B
SCHEMBL13288768 0.86 CDK2 (0.54) CDK2GSK3BSMN1; SMN2MMP13KMT2A
SCHEMBL13288769 0.86 CDK2 (0.55) CDK2GSK3BPDE2APDE10AKMT2A
SCHEMBL13288668 0.86 CDK2 (0.55) CDK2GSK3BSMN1; SMN2PDE2APDE10A
SCHEMBL13119595 0.85 CDK2 (0.61) CDK2GSK3BKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2194058-A1 Pyrazolopyrimidines suitable for the treatment of cancer diseases SCHERING CORPORATION (US) 2010-06-09 — — EP disclosed
Send feedback